Feldco

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feldco

Quick Facts

Property Description
Active ingredient Piroxicam
Form Capsule, Tablet, Gel, Solution for Injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic

What is Feldco and Its Core Identity?

Feldco is a commercial pharmaceutical preparation containing the active pharmaceutical ingredient, Piroxicam, which is a prescription-only medication. Piroxicam is a synthetic small molecule compound that functions as the sole active agent in this product, defining its therapeutic profile. It is typically administered via the oral route as a capsule or tablet for systemic effect, though a topical gel is also widely available for localized application. The versatility of these administration routes is clinically recognized for facilitating tailored treatment approaches for pain management.

Piroxicam's Classification as an Oxicam-Type NSAID

Piroxicam is classified pharmacologically as a Nonsteroidal Anti-inflammatory Drug (NSAID), a category utilized globally for pain and swelling management. However, it belongs to the distinct oxicam group, which are structurally categorized as enolic acids. Pharmacological studies have confirmed that this oxicam structure results in a relatively long elimination half-life, a primary differentiating factor of Piroxicam from many other, shorter-acting NSAIDs. This characteristic provides sustained therapeutic activity, allowing the drug to maintain consistent symptomatic relief.

What is the General Purpose of This Type of Medicine?

The general purpose of this type of medicine is to deliver anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effects. Its mechanism involves acting as a non-selective Cyclooxygenase (COX) inhibitor, which effectively decreases the synthesis of pro-inflammatory prostaglandins. By modulating these fundamental signals, the medication helps to relieve chronic discomfort and tenderness, thereby supporting improved mobility and function in patients experiencing prolonged inflammatory conditions.

What side effects are possible with Feldco?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential risks of Feldco based on their severity and frequency. This information reflects the adverse reactions and safety constraints documented by government agencies.

Serious Safety Risks

Feldco is associated with several serious, potentially life-threatening risks, which are highlighted by regulatory bodies:

  • Cardiovascular Thrombotic Events: Use may increase the risk of serious events such as heart attack and stroke. This risk can increase with the duration of use. The medicine is contraindicated for the treatment of pain right before and after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal (GI) Risk: Serious GI events, including bleeding, ulceration, and perforation of the stomach or intestines, have been documented. These events can occur without warning and may be fatal. The risk is generally higher in the elderly and with prolonged use.
  • Severe Skin Reactions: Rare but serious skin reactions, such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), require immediate discontinuation of the medicine.

Common Adverse Reactions

The most commonly reported adverse reactions in clinical trials (incidence greater than 2%) include nausea, constipation, flatulence, abdominal pain, diarrhea, headache, dizziness, edema, and rash.

Population-Specific Constraints

Regulatory documents emphasize specific considerations for certain patient groups:

  • Elderly Patients: Identified as a high-risk group, particularly for fatal GI complications.
  • Pregnancy: Use is generally avoided from the 30th week of pregnancy onward due to documented risks to the developing fetus, including the potential for premature closure of a fetal blood vessel (ductus arteriosus).
  • Contraindications: The medicine is contraindicated in patients who have experienced allergic-type reactions (e.g., asthma, hives) after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).

Overdose and Emergency Response

Overdose Manifestations

Feldco (Piroxicam) overdose involves specific clinical signs documented in official regulatory labeling. Initial manifestations may include gastrointestinal disturbances such as nausea, vomiting, stomach pain, and diarrhea. Central Nervous System (CNS) effects are also documented, often presenting as severe headache, dizziness, unsteadiness, or confusion. Changes in breathing patterns and sensory symptoms like ringing in the ears (tinnitus) are also recognized in the official profile.

Severe Outcomes and Emergency Action

The primary regulatory concern is the potential for severe or life-threatening systemic outcomes. These include serious gastrointestinal events like bleeding, ulceration, and perforation, which have been documented as fatal in some instances. Furthermore, severe overdose may progress to acute renal failure, low blood pressure (shock), and severe CNS depression, including seizures or coma. Population-specific notes indicate that older adults and children are considered higher-risk.

Regulatory authorities mandate that if an overdose is suspected, individuals must immediately call the Poison Help hotline or local emergency services. No specific antidote is known for Piroxicam, and therefore, the official treatment protocol is entirely supportive and symptomatic. Management requires hospital monitoring, including the observation of vital signs and laboratory evaluation of organ function.

Therapeutic Uses of Feldco

Feldco, which contains Piroxicam, is generally used to help with symptomatic relief across several key therapeutic domains characterized by symptoms related to physical discomfort and inflammation. Its purpose is to contribute to easing the overall symptom load, and may help patients cope more steadily with symptom fluctuations.

It is commonly used across conditions characterized by periods of heightened symptoms such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It is also considered relevant in addressing acute episodes like Gouty Arthritis or managing cyclical pain associated with Primary Dysmenorrhea.

“The role of this medication is to help provide supportive relief and address symptom clusters that may become intense or disruptive.”

Applied across domains where additional symptomatic support is needed, the medicine focuses on reducing symptoms like persistent joint pain, swelling, and stiffness. It may assist with maintaining functional stability when symptoms escalate temporarily, thereby supporting patients during episodes of heightened discomfort.


Quick Fact: Relief for Inflammation and Joint Stiffness The medication is relevant for easing symptoms that interfere with daily comfort in conditions where functional stability becomes affected.

Regulatory References

  1. NIH MedlinePlus Drug Information on Piroxicam

Eligibility and Restrictions for Use

Who can and cannot use Feldco? (Piroxicam)

Official regulatory documents strictly define the patient groups permitted to use Feldco (Piroxicam) and those for whom use is prohibited. Systemic use is generally allowed for adults to manage symptoms of conditions like Osteoarthritis and Rheumatoid Arthritis.

Contraindications and Prohibited Use

Feldco is contraindicated (must not be used) in several patient populations, including those with:

  • Known Hypersensitivity: History of asthma, urticaria, or severe allergic-type reactions after taking aspirin or any other NSAID.
  • Gastrointestinal History: Active peptic ulceration, gastrointestinal bleeding, or a prior history of serious GI events.
  • Cardiovascular Conditions: Severe heart failure or for treating pain following Coronary Artery Bypass Graft (CABG) surgery.
  • Pregnancy Status: Use is strictly prohibited during the third trimester of pregnancy (starting at about 30 weeks gestation).

Age-Related and Conditional Restrictions

Population Group Eligibility Status
Pediatric Patients Use is not recommended; safety and efficacy are not established (e.g., under 16 years).
Older Adults Administration to patients older than 80 years should be avoided due to high complication risk.
Organ Impairment Contraindicated in severe renal failure or severe hepatic failure.

What should I know about interactions with other medicines?

The official regulatory profile for Feldco defines mandatory constraints and documented outcomes based on its Nonsteroidal Anti-inflammatory Drug (NSAID) classification. Co-administration is formally contraindicated with other systemic NSAIDs, including COX-2 inhibitors, and with aspirin when used at analgesic doses. Feldco is also prohibited for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

The drug has a documented pharmacodynamic interaction with substances that interfere with hemostasis, such as oral anticoagulants and antiplatelet agents, which increases the official risk of bleeding. Feldco may also diminish the therapeutic effect of antihypertensive agents, including ACE Inhibitors, ARBs, and Diuretics, which impacts the regulation of fluid retention and blood pressure.

The pharmacokinetic profile is characterized by metabolism primarily through the CYP2C9 enzyme. This clearance pathway is associated with population-specific cautions: individuals identified as poor CYP2C9 metabolizers may exhibit abnormally high systemic plasma levels due to reduced metabolic clearance. Furthermore, Feldco has been shown to increase the plasma concentration of co-administered drugs like Digoxin. The regulatory documentation notes that co-ingestion with alcohol increases the risk of serious gastrointestinal complications, whereas food causes only a slight delay in the rate of absorption.

Mechanism of Action

Piroxicam, the active component in Feldco, exerts its activity by engaging in two main mechanistic domains: the direct modulation of lipid mediator synthesis and the resulting modulation of peripheral and central signaling pathways. The drug's action is defined by a non-selective interaction at the molecular level.

Modulation of Eicosanoid Synthesis via COX Inhibition

The fundamental mechanism involves the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically both the COX-1 and COX-2 isoforms. By blocking the active site of these enzymes, Piroxicam suppresses the conversion of arachidonic acid into prostaglandins and thromboxanes. This action modifies the early molecular steps that shape systemic physiological outcomes.

Modulation of Peripheral Nociception and Central Thermoregulation

The resulting reduction in prostaglandin levels directly reduces the excitability threshold of peripheral nociceptors at the tissue level, contributing to the modulation of activity within targeted physiological pathways. Simultaneously, the mechanism influences pathways in the central nervous system (CNS), specifically in the hypothalamus that regulate the body’s temperature set point. This dual-action modulation is characteristic of Piroxicam's effect on inflammatory and thermoregulatory pathways.

Dosage and Administration Information

Feldco (Piroxicam) is generally administered via the oral route as a capsule or tablet. The standard regimen for chronic conditions, such as rheumatoid arthritis and osteoarthritis, is typically a single dose of 20 mg taken once daily. This once-daily frequency is established to maintain stable systemic drug levels due to the drug's long elimination half-life. While a single intake is common, the total daily dose may be administered as a divided schedule (e.g., 10 mg twice daily). The general principle guiding administration is the use of the lowest effective dose for the shortest duration necessary for symptomatic stabilization.

For proper administration, the oral capsule must be swallowed whole with a full glass of water, and should be taken with or after food. Patients should be aware that the full therapeutic effect is typically not assessed for approximately two weeks, corresponding to the time required to reach steady-state plasma concentrations. If continued long-term treatment is pursued, the necessity and safety of the therapy must be re-evaluated frequently.

Specific dose considerations apply to certain populations. Patients with known or suspected impaired kidney or liver function, as well as individuals identified as CYP2C9 poor metabolizers, should have their dose carefully considered and potentially reduced. In the procedural event of a missed dose, the next scheduled dose should be taken as normal, and the previous dose should not be doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Feldco

The research evidence for Feldco (Piroxicam) comes primarily from official regulatory reviews, randomized controlled trials (RCTs), and systematic reviews. The available evidence, which is strictly observational and non-advisory, contributes to understanding symptom patterns that have been observed so far in specific patient groups under controlled conditions.

Evidence for use in Chronic Arthritis (Rheumatoid Arthritis and Osteoarthritis)

A large body of evidence was studied for Feldco's evaluation in conditions characterized by fluctuating or episodic manifestations of inflammation, joint stiffness, and physical discomfort. The research included numerous short-term to intermediate-term Randomized Controlled Trials (RCTs). These trials monitored various outcomes related to physical discomfort, including changes in reported pain intensity, measurements of joint swelling and stiffness, and patient-reported outcomes describing perceived discomfort via functional scales. Studies were conducted in adults, often including detailed subgroup analysis for older adults.

Findings describe patterns observed in the studies that were generally related to the measurement of symptomatic changes over the observation period. Most trials report how symptoms evolved in the observed populations, often comparing Piroxicam against a placebo or another study compound. This evidence contributes to understanding symptom patterns, but the studies were mainly designed to assess changes in symptoms and do not monitor long-term outcomes of the underlying disease process itself.

Evidence for use in Ankylosing Spondylitis and Acute Symptoms

Feldco was evaluated in patients with Ankylosing Spondylitis (AS), a condition marked by functional limitations and spinal pain. Research examined the use in studies focusing on episodes where symptoms become more noticeable, monitoring outcomes like back pain scores and changes in functional activity levels. Evidence is also available from short-term RCTs for acute symptom patterns, such as for acute gout flares. However, the regulatory review of this evidence, while examining symptomatic measurements, noted factors that led to restrictions on the systemic use of Feldco for general acute conditions in many regions. Current evidence for systemic use is largely focused on the chronic inflammatory conditions, reflecting the regulatory context surrounding the evidence profile for brief, general acute use.

Long-Term Studies and Follow-up Duration

Most research exploring how symptoms change over time for chronic conditions has a primary follow-up duration of 6 to 12 weeks. Evidence for longer-term use, extending beyond one year, primarily comes from observational studies and ongoing post-marketing surveillance. Research provides insight into short-term changes that can be measured, but long-term follow-up findings are not fully established by numerous controlled studies designed specifically for monitoring symptom measurement over many years.

Evidence in Specific Populations

  • Older Adults: The available research includes data from studies that enrolled older adults with chronic arthritis. Findings describe patterns observed in these groups.
  • Pediatric Population: Research describing the efficacy or safety of systemic Piroxicam has limited availability in the pediatric population. Regulatory information suggests that appropriate studies in children are lacking, meaning that data for this group remain insufficient.
  • Pregnancy: Studies exploring the effects on pregnancy are not part of the standard efficacy review and were not designed to monitor these outcomes.

What is Still Uncertain About Feldco Research

Scientific literature and regulatory reviews consistently point to several areas where the evidence remains limited, heterogeneous, or incomplete:

  • Long-Term Efficacy: Follow-up durations were limited in many initial efficacy trials, meaning that long-term outcomes are not well characterized by controlled data.
  • Disease Progression: The available evidence is focused on symptomatic relief and does not contribute to understanding whether the medication alters the underlying course or progression of chronic diseases like OA or RA.
  • Comparative Standing: Comparative evidence is lacking for a full assessment against the entire range of current treatment alternatives.
  • General Acute Use: The evidence for general, non-specific acute pain management is noted to have limited scope for supporting its systemic use in this context, leading to restrictions for this indication.

Key Studies & References

  1. Piroxicam (oral route) - Drug Information (Addressing pediatric use and general indications)
  2. Piroxicam: new restrictions, including specialist initiation (UK Regulatory Update on systemic use)

Frequently Asked Questions (FAQ)

Common questions about Feldco (FAQ)


Q: Are there any specific food items or beverages that should be avoided while taking Feldco?

According to official regulatory documents, the co-ingestion with alcohol is associated with an increased risk of serious gastrointestinal complications. There are no specific warnings against non-alcoholic foods or beverages.


Q: Are there any required medical tests or monitoring needed while taking Feldco?

Official regulatory documents describe the need for monitoring certain health indicators for patients using Feldco long-term or those with specific health conditions. These described monitoring areas can include checking blood pressure, assessment of renal function (kidney function), and evaluation of hemoglobin or hematocrit (blood count) for signs of anemia.


Q: Is it true that Feldco may cause weight changes, like gain or loss?

Official product information states that edema (fluid retention or swelling) is a commonly reported adverse reaction. Regulatory documents emphasize that the medication should be used with caution in patient populations with fluid retention or existing heart conditions.


Q: How long after stopping Feldco will the drug completely leave my system?

The active ingredient in Feldco, piroxicam, has a relatively long plasma half-life of approximately 50 hours. Because of this sustained activity, it typically takes several days for the medicine to be fully eliminated from the body after the last dose.


Q: Does Feldco affect the performance of activities that require concentration, like driving?

Official regulatory information lists side effects such as dizziness and headache as potential adverse reactions. The documents note that these effects may impair the ability to perform tasks that require concentration, such as driving or operating machinery.


Q: How does Feldco compare to Drug X, which treats the same condition? (Neutral comparison)

Feldco contains piroxicam, which is classified as an oxicam-type Nonsteroidal Anti-inflammatory Drug (NSAID). The primary differentiating feature noted in official documentation is its long elimination half-life, which enables the drug to maintain effects with once-daily administration.


Q: Is it common to experience nausea or digestive upset when first starting Feldco?

Common adverse reactions listed in official documents include nausea, abdominal pain, and diarrhea, with an incidence greater than two percent. However, regulatory texts do not specifically indicate whether these digestive issues are more severe during the very first days of use.


Q: What are the non-directive guidelines for taking Feldco if I have trouble swallowing pills?

The official administration guidelines for the capsule form state that it must be swallowed whole with a full glass of water. Piroxicam is also available in different forms, such as a topical gel for localized application, which may be an alternative depending on the condition being addressed.


Q: Were the original studies on Feldco conducted on a diverse patient demographic?

Clinical trials included studies on a broad range of adults, often with specific detailed subgroup analysis for older adults. The official regulatory documents do not routinely provide detailed data on diversity metrics such as race or ethnicity for the original trials.


Q: Does Feldco cause any noticeable changes in energy levels or mood?

Some regulatory guidance notes rare adverse reactions such as mood alterations and restlessness. Additionally, general effects like fatigue or drowsiness have been reported in some observed populations.


Q: Is there a generic version of Feldco available for purchase?

Yes, the active ingredient in Feldco is piroxicam. Piroxicam has been available in a generic formulation since 1992 and is sold globally under various different brand names.


Q: Is there a specific patient guide or leaflet provided by the government for Feldco?

Yes, a Medication Guide containing important safety information on the use of Piroxicam is required by regulatory bodies to be provided to the patient at the time of dispensing.


Q: Does taking Feldco impact or alter the results of any common lab tests?

Official information indicates that Piroxicam can cause mild elevations of certain substances in the blood, such as serum aminotransferase elevations, which may be reflected in the results of standard liver function tests.


Q: Can people with a history of mental health issues use Feldco?

Some rare adverse reactions noted in official documentation include mood alterations and restlessness. However, there are no broad, explicit contraindications based solely on a person's history of mental health conditions.


Q: Does Feldco have a known effect on sleep patterns or insomnia?

Regulatory guidance lists drowsiness as a potential side effect. This may be related to the drug's known effects on the central nervous system, which could indirectly affect sleep patterns.

How should Feldco be stored and disposed of?

How to Store and Dispose of Feldene (Piroxicam)

Feldene capsules must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The product must be protected from excess heat and moisture and kept in a dry place. It is required to store the medication in its original container and ensure it remains tightly closed.

For child safety, the medicine must be stored out of the sight and reach of children and pets.

Unused or expired Feldene should be disposed of via an authorized drug take-back program. If this is not possible, the medicine must be mixed with an undesirable substance, sealed in a container, and placed in the household trash, following specific regulatory procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Feldco found in:

A-Z Index: